Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma

Ryan A. Metcalf, Ahmad Monabati, Monika Vyas, Giovanna Roncador, Gabriela Gualco, Carlos E. Bacchi, Sheren F. Younes, Yasodha Natkunam, Aharon G. Freud

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

The diagnosis of marginal zone lymphomas (MZL) is challenged by the lack of specific markers that distinguish them from other low-grade non-Hodgkin B-cell lymphomas. Myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein that labels myelomonocytic cells as well as B lymphocytes that localize to the marginal zone areas of splenic white pulp. We evaluated MNDA expression in a large series of B-cell lymphomas to assess the sensitivity and specificity of this antigen for the characterization of MZL. A total of 440 tissue sections containing extramedullary B-cell lymphomas and 216 bone marrow biopsies containing atypical or neoplastic lymphoid infiltrates were stained for MNDA by immunohistochemistry. Among the extramedullary lymphoma cases, approximately 67% of nodal MZL, 61% of extranodal MZL, and 24% of splenic MZL expressed MNDA. MNDA was also infrequently expressed in other B-cell neoplasms including mantle cell lymphoma (6%), chronic lymphocytic leukemia/small lymphocytic lymphoma (13%), follicular lymphoma (FL) (4%), lymphoplasmacytic lymphoma (25%), and diffuse large B-cell lymphoma (3%). In contrast, MNDA was only expressed in 2.3% of all bone marrow biopsies involved by lymphoid infiltrates, including 2 cases of FL and one case of MZL. Collectively, these data support the inclusion of MNDA in the diagnostic evaluation of extramedullary B-cell lymphomas, particularly those in which the differential diagnosis is between low-grade FL and MZL.

Original languageEnglish
Pages (from-to)1730-1736
Number of pages7
JournalHuman Pathology
Volume45
Issue number8
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Nuclear Antigens
Follicular Lymphoma
Differentiation Antigens
Myeloid Cells
Cell Differentiation
Lymphoma
Differential Diagnosis
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
B-Lymphocytes
Bone Marrow
Biopsy
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Nuclear Proteins
Immunohistochemistry
Antigens
Sensitivity and Specificity

Keywords

  • B cell
  • Follicular lymphoma
  • Lymphoid neoplasia
  • Lymphoma
  • Marginal zone lymphoma
  • MNDA
  • Non-Hodgkin lymphoma

Cite this

Metcalf, Ryan A. ; Monabati, Ahmad ; Vyas, Monika ; Roncador, Giovanna ; Gualco, Gabriela ; Bacchi, Carlos E. ; Younes, Sheren F. ; Natkunam, Yasodha ; Freud, Aharon G. / Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. In: Human Pathology. 2014 ; Vol. 45, No. 8. pp. 1730-1736.
@article{c561b6405eb944a683d6bd58ef92af51,
title = "Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma",
abstract = "The diagnosis of marginal zone lymphomas (MZL) is challenged by the lack of specific markers that distinguish them from other low-grade non-Hodgkin B-cell lymphomas. Myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein that labels myelomonocytic cells as well as B lymphocytes that localize to the marginal zone areas of splenic white pulp. We evaluated MNDA expression in a large series of B-cell lymphomas to assess the sensitivity and specificity of this antigen for the characterization of MZL. A total of 440 tissue sections containing extramedullary B-cell lymphomas and 216 bone marrow biopsies containing atypical or neoplastic lymphoid infiltrates were stained for MNDA by immunohistochemistry. Among the extramedullary lymphoma cases, approximately 67{\%} of nodal MZL, 61{\%} of extranodal MZL, and 24{\%} of splenic MZL expressed MNDA. MNDA was also infrequently expressed in other B-cell neoplasms including mantle cell lymphoma (6{\%}), chronic lymphocytic leukemia/small lymphocytic lymphoma (13{\%}), follicular lymphoma (FL) (4{\%}), lymphoplasmacytic lymphoma (25{\%}), and diffuse large B-cell lymphoma (3{\%}). In contrast, MNDA was only expressed in 2.3{\%} of all bone marrow biopsies involved by lymphoid infiltrates, including 2 cases of FL and one case of MZL. Collectively, these data support the inclusion of MNDA in the diagnostic evaluation of extramedullary B-cell lymphomas, particularly those in which the differential diagnosis is between low-grade FL and MZL.",
keywords = "B cell, Follicular lymphoma, Lymphoid neoplasia, Lymphoma, Marginal zone lymphoma, MNDA, Non-Hodgkin lymphoma",
author = "Metcalf, {Ryan A.} and Ahmad Monabati and Monika Vyas and Giovanna Roncador and Gabriela Gualco and Bacchi, {Carlos E.} and Younes, {Sheren F.} and Yasodha Natkunam and Freud, {Aharon G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.humpath.2014.04.004",
language = "English",
volume = "45",
pages = "1730--1736",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "8",

}

Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma. / Metcalf, Ryan A.; Monabati, Ahmad; Vyas, Monika; Roncador, Giovanna; Gualco, Gabriela; Bacchi, Carlos E.; Younes, Sheren F.; Natkunam, Yasodha; Freud, Aharon G.

In: Human Pathology, Vol. 45, No. 8, 01.01.2014, p. 1730-1736.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma

AU - Metcalf, Ryan A.

AU - Monabati, Ahmad

AU - Vyas, Monika

AU - Roncador, Giovanna

AU - Gualco, Gabriela

AU - Bacchi, Carlos E.

AU - Younes, Sheren F.

AU - Natkunam, Yasodha

AU - Freud, Aharon G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The diagnosis of marginal zone lymphomas (MZL) is challenged by the lack of specific markers that distinguish them from other low-grade non-Hodgkin B-cell lymphomas. Myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein that labels myelomonocytic cells as well as B lymphocytes that localize to the marginal zone areas of splenic white pulp. We evaluated MNDA expression in a large series of B-cell lymphomas to assess the sensitivity and specificity of this antigen for the characterization of MZL. A total of 440 tissue sections containing extramedullary B-cell lymphomas and 216 bone marrow biopsies containing atypical or neoplastic lymphoid infiltrates were stained for MNDA by immunohistochemistry. Among the extramedullary lymphoma cases, approximately 67% of nodal MZL, 61% of extranodal MZL, and 24% of splenic MZL expressed MNDA. MNDA was also infrequently expressed in other B-cell neoplasms including mantle cell lymphoma (6%), chronic lymphocytic leukemia/small lymphocytic lymphoma (13%), follicular lymphoma (FL) (4%), lymphoplasmacytic lymphoma (25%), and diffuse large B-cell lymphoma (3%). In contrast, MNDA was only expressed in 2.3% of all bone marrow biopsies involved by lymphoid infiltrates, including 2 cases of FL and one case of MZL. Collectively, these data support the inclusion of MNDA in the diagnostic evaluation of extramedullary B-cell lymphomas, particularly those in which the differential diagnosis is between low-grade FL and MZL.

AB - The diagnosis of marginal zone lymphomas (MZL) is challenged by the lack of specific markers that distinguish them from other low-grade non-Hodgkin B-cell lymphomas. Myeloid cell nuclear differentiation antigen (MNDA) is a nuclear protein that labels myelomonocytic cells as well as B lymphocytes that localize to the marginal zone areas of splenic white pulp. We evaluated MNDA expression in a large series of B-cell lymphomas to assess the sensitivity and specificity of this antigen for the characterization of MZL. A total of 440 tissue sections containing extramedullary B-cell lymphomas and 216 bone marrow biopsies containing atypical or neoplastic lymphoid infiltrates were stained for MNDA by immunohistochemistry. Among the extramedullary lymphoma cases, approximately 67% of nodal MZL, 61% of extranodal MZL, and 24% of splenic MZL expressed MNDA. MNDA was also infrequently expressed in other B-cell neoplasms including mantle cell lymphoma (6%), chronic lymphocytic leukemia/small lymphocytic lymphoma (13%), follicular lymphoma (FL) (4%), lymphoplasmacytic lymphoma (25%), and diffuse large B-cell lymphoma (3%). In contrast, MNDA was only expressed in 2.3% of all bone marrow biopsies involved by lymphoid infiltrates, including 2 cases of FL and one case of MZL. Collectively, these data support the inclusion of MNDA in the diagnostic evaluation of extramedullary B-cell lymphomas, particularly those in which the differential diagnosis is between low-grade FL and MZL.

KW - B cell

KW - Follicular lymphoma

KW - Lymphoid neoplasia

KW - Lymphoma

KW - Marginal zone lymphoma

KW - MNDA

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84904611230&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.04.004

DO - 10.1016/j.humpath.2014.04.004

M3 - Article

VL - 45

SP - 1730

EP - 1736

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 8

ER -